Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian H Kushner

Showing results (91-100 of 103) with videos related to

Pageof 11
Sort By:
Practical Radiation Oncology|February 4, 2024
Intraoperative Radiation Therapy for Relapsed or Refractory High-Risk Neuroblastoma: A 27-Year ExperienceBrianna Conte, Dana L Casey, Kathryn R Tringale, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2003
Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adultsE Anders Kolb, Brian H Kushner, Richard Gorlick, et al.
International Journal of Radiation Oncology, Biology, Physics|October 21, 2025
Local Control With Reduced-Dose Radiation Therapy for High-Risk Neuroblastoma: Results From a Prospective Clinical TrialChristopher B Jackson, Dana L Casey, Brian H Kushner, et al.
Journal of Neuro-Oncology|November 6, 2009
Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastomaKim Kramer, Brian H Kushner, Shakeel Modak, et al.
Journal of Pediatric Surgery|October 6, 2010
Preliminary results of a phase I trial of prophylactic ethanol-lock administration to prevent mediport catheter-related bloodstream infectionsMark L Kayton, Edward G Garmey, Nicole M Ishill, et al.
Nature Communications|February 14, 2025
The anti-GD2 monoclonal antibody naxitamab plus GM-CSF for relapsed or refractory high-risk neuroblastoma: a phase 2 clinical trialJaume Mora, Godfrey C F Chan, Daniel A Morgenstern, et al.
Oncoimmunology|September 18, 2018
Adoptive immunotherapy with haploidentical natural killer cells and Anti-GD2 monoclonal antibody m3F8 for resistant neuroblastoma: Results of a phase I studyShakeel Modak, Jean-Benoit Le Luduec, Irene Y Cheung, et al.
Cancer|September 14, 2022
Early-phase clinical trial eligibility and response evaluation criteria for refractory, relapsed, or progressive neuroblastoma: A consensus statement from the National Cancer Institute Clinical Trials Planning MeetingJulie R Park, Judith G Villablanca, Barbara Hero, et al.
Pediatric Blood & Cancer|July 5, 2024
Ovarian function in female survivors of high-risk neuroblastomaLauren Jimenez-Kurlander, Amelia DeRosa, Caroline E Kostrzewa, et al.
Plos One|June 6, 2017
A phase I study of single-agent perifosine for recurrent or refractory pediatric CNS and solid tumorsOren J Becher, Nathan E Millard, Shakeel Modak, et al.
Pageof 11

Showing results (91-100 of 103) with videos related to

Sort By:
Pageof 11
Practical Radiation Oncology|February 4, 2024
Intraoperative Radiation Therapy for Relapsed or Refractory High-Risk Neuroblastoma: A 27-Year ExperienceBrianna Conte, Dana L Casey, Kathryn R Tringale, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 16, 2003
Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adultsE Anders Kolb, Brian H Kushner, Richard Gorlick, et al.
International Journal of Radiation Oncology, Biology, Physics|October 21, 2025
Local Control With Reduced-Dose Radiation Therapy for High-Risk Neuroblastoma: Results From a Prospective Clinical TrialChristopher B Jackson, Dana L Casey, Brian H Kushner, et al.
Journal of Neuro-Oncology|November 6, 2009
Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastomaKim Kramer, Brian H Kushner, Shakeel Modak, et al.
Journal of Pediatric Surgery|October 6, 2010
Preliminary results of a phase I trial of prophylactic ethanol-lock administration to prevent mediport catheter-related bloodstream infectionsMark L Kayton, Edward G Garmey, Nicole M Ishill, et al.
Nature Communications|February 14, 2025
The anti-GD2 monoclonal antibody naxitamab plus GM-CSF for relapsed or refractory high-risk neuroblastoma: a phase 2 clinical trialJaume Mora, Godfrey C F Chan, Daniel A Morgenstern, et al.
Oncoimmunology|September 18, 2018
Adoptive immunotherapy with haploidentical natural killer cells and Anti-GD2 monoclonal antibody m3F8 for resistant neuroblastoma: Results of a phase I studyShakeel Modak, Jean-Benoit Le Luduec, Irene Y Cheung, et al.
Cancer|September 14, 2022
Early-phase clinical trial eligibility and response evaluation criteria for refractory, relapsed, or progressive neuroblastoma: A consensus statement from the National Cancer Institute Clinical Trials Planning MeetingJulie R Park, Judith G Villablanca, Barbara Hero, et al.
Pediatric Blood & Cancer|July 5, 2024
Ovarian function in female survivors of high-risk neuroblastomaLauren Jimenez-Kurlander, Amelia DeRosa, Caroline E Kostrzewa, et al.
Plos One|June 6, 2017
A phase I study of single-agent perifosine for recurrent or refractory pediatric CNS and solid tumorsOren J Becher, Nathan E Millard, Shakeel Modak, et al.
Pageof 11